Source - RNS
RNS Number : 2555J
Motif Bio PLC
08 September 2016
 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

This announcement contains inside information.

 

Motif Bio plc

("Motif Bio" or the "Company")

 

8 September 2016

 

UPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL

 

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces an update to REVIVE-1, one of Motif Bio's two Phase 3 clinical trials currently enrolling patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

 

Patient enrollment for REVIVE-1 has exceeded projections and data readout is now expected in the second quarter of 2017, rather than the second half of 2017, as previously stated. REVIVE-2 remains on track with data readout continuing to be expected in the second half of 2017.

 

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

For further information please contact:

 

Motif Bio plc

Richard Morgan (Chairman)

Graham Lumsden (Chief Executive Officer)

 

[email protected]

 

Zeus Capital Limited (NOMAD & BROKER)

Phil Walker/Giles Balleny

Dominic Wilson

 

+44 (0)20 3829 5000

Northland Capital Partners Limited (BROKER)

Patrick Claridge/ David Hignell

John Howes/ Rob Rees (Broking)

 

+44 (0)20 3861 6625

Walbrook PR Ltd. (FINANCIAL PR & IR)

Paul McManus

Mike Wort

+44 (0)20 7933 8780 or [email protected]

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002



MC Services AG (EUROPEAN IR)


Raimund Gabriel

+49 (0)89 210 2280

 

 

 

 

 

About Motif Bio

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an intravenous formulation of iclaprim, for the treatment of ABSSSI, which are expected to be completed in 2017.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFLVAVIDIIR